Recent insider trends for Bristol-Myers Squibb Company (NYSE:BMY) have caught the attention of investors. Insider data is useful because it can reveal what a company’s executives and largest shareholders feel about a stock. In this case, the data has some interesting things to say about how BMY might perform in the future.
Institutions own 70.24% of Bristol-Myers Squibb Company (BMY)’s shares. The total value of these holdings, in millions, is $71,966. Among active positions in the latest quarter, 676 holders increased their positions by a total of 65.85 million shares, 747 holders decreased the positions by a total of 94.94 million shares, and 261 holders held their positions. This works out to a net decrease in ownership of 29.09 million shares, and suggests that institutions are feeling bearish about the stock.
Among new and sold out positions, 107 holders initiated new positions by a total of 4.49 million shares and 84 holders exited their positions by a total of 11.37 million shares. This nets out to a decrease of 6.88 million shares and is another bearish sign for BMY.
In the last three months, insiders executed a total of 4 trades. 1 of these were buys and 3 were sells. Insider ownership decreased by a total of 4960 shares, which suggests that BMY’s key executives are feeling less optimistic about the outlook for the stock. The data from the past twelve months tells a similar story: insiders executed 17 buys and 30 sells, and ownership decreased by a net of 479247 shares.
Short interest is another tool that analysts use to gauge investor sentiment. It represents the number of a stock’s shares that are being shorted by investors. Bristol-Myers Squibb Company (NYSE:BMY)’s short interest is 10.09 million shares, or % of the float. This represents an increase of 1% in the number of shares being shorted compared to the previous reading, and implies that investors felt more pessimistic about the stock during the past two weeks.
Ownership trends and trading patterns can be useful tools for predicting a stock’s performance, but it’s also important to consider the technicals in order to form a more comprehensive view. A composite of 13 technical indicators that includes measures such as moving averages and momentum oscillators suggests that BMY is a Strong buy, which implies that BMY is expected to outperform the market based on prior trading patterns.
Institutional ownership trends suggest that the stock is cheap and the insider trading data indicates that insiders are bearish. Technical indicators (also) suggest that Bristol-Myers Squibb Company (NYSE:BMY) is undervalued.